These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37406505)

  • 1. Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics.
    Babalola BA; Akinsuyi OS; Folajimi EO; Olujimi F; Otunba AA; Chikere B; Adewumagun IA; Adetobi TE
    Biomed Pharmacother; 2023 Sep; 165():115099. PubMed ID: 37406505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing antibodies against COVID-19.
    Zhou D; Ren J; Fry EE; Stuart DI
    Curr Opin Virol; 2023 Aug; 61():101332. PubMed ID: 37285620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.
    Li PY; Li SQ; Gao SG; Dong DY
    Med Hypotheses; 2022 Feb; 159():110754. PubMed ID: 35002020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection.
    Qiao Y; Wotring JW; Zhang CJ; Jiang X; Xiao L; Watt A; Gattis D; Scandalis E; Freier S; Zheng Y; Pretto CD; Ellison SJ; Swayze EE; Guo S; Sexton JZ; Chinnaiyan AM
    PLoS One; 2023; 18(2):e0281281. PubMed ID: 36735698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.
    Singh DD; Parveen A; Yadav DK
    Front Cell Infect Microbiol; 2021; 11():777212. PubMed ID: 34970509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies.
    Gattinger P; Ohradanova-Repic A; Valenta R
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intranasal ASO therapeutic targeting SARS-CoV-2.
    Zhu C; Lee JY; Woo JZ; Xu L; Nguyenla X; Yamashiro LH; Ji F; Biering SB; Van Dis E; Gonzalez F; Fox D; Wehri E; Rustagi A; Pinsky BA; Schaletzky J; Blish CA; Chiu C; Harris E; Sadreyev RI; Stanley S; Kauppinen S; Rouskin S; Näär AM
    Nat Commun; 2022 Aug; 13(1):4503. PubMed ID: 35922434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
    Wang F; Li L; Dou Y; Shi R; Duan X; Liu H; Zhang J; Liu D; Wu J; He Y; Lan J; Lu B; Feng H; Yan J
    Emerg Microbes Infect; 2022 Dec; 11(1):548-551. PubMed ID: 35060840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.
    Chu X; Ding X; Yang Y; Lu Y; Li T; Gao Y; Zheng L; Xiao H; Yang T; Cheng H; Huang H; Liu Y; Lou Y; Wu C; Chen Y; Yang H; Ji X; Guo H
    Biochem Biophys Res Commun; 2023 Jun; 660():43-49. PubMed ID: 37062240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs.
    Shah M; Woo HG
    Mol Ther; 2022 Oct; 30(10):3101-3105. PubMed ID: 36087577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
    He X; Zeng XX
    Drug Des Devel Ther; 2022; 16():951-972. PubMed ID: 35386853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
    Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
    Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in antibody-based immunotherapy strategies for COVID-19.
    Esmaeilzadeh A; Rostami S; Yeganeh PM; Tahmasebi S; Ahmadi M
    J Cell Biochem; 2021 Oct; 122(10):1389-1412. PubMed ID: 34160093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies.
    Huang Q; Han X; Yan J
    Emerg Microbes Infect; 2022 Dec; 11(1):2412-2422. PubMed ID: 36106670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.